Many uncertainties remain in the long-term care of sickle cell disease–pulmonary hypertension
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
To the Editor We read with great interest the recent publication by Savale et al.1 in this month’s issue of the American Journal of Respiratory and Critical Care Medicine. This important work adds valuable long-term follow-up data in a well-characterized population of patients with sickle cell disease (SCD) undergoing systematic screening for pulmonary hypertension (PH) including right heart catheterization (RHC).2 As is no surprise to clinicians caring for patients with SCD, patients with SCD-PH face an enhanced risk of mortality even at levels of pulmonary vasculopathy less severe than current guideline definitions of precapillary PH.3 Fittingly, PH/heart failure was the most common cause of death in the overall cohort.1 However, several issues limit the utility of using a single time point for assessing the probability of PH: for instance, individual echocardiograms may under- or overestimate tricuspid regurgitant jet velocity (TRV) and, unfortunately, PH is a progressive disease. Longitudinal studies in other populations at high risk of PH (such as scleroderma4) have shown that interval development of PH is common, even in subjects initially considered to be at lower risk of PH. Similarly, classifications may change over time. The well-recognized prevalence of left ventricular diastolic dysfunction means that post-capillary and pre-capillary determinants of PH may emerge over time. The long-term impact on PH physiology is unclear without repeat hemodynamic assessments. The survival curves presented exclude the group of patients with isolated post-capillary pulmonary hypertension. All these factors contribute to ongoing uncertainties in this population. Accordingly, many questions persist. Of patients initially considered to be low risk for PH (ie, group a subjects with TRV < 2.5 m/s), what percentage later developed an elevated TRV on follow-up screening such that RHC was recommended? Of those initially stratified to group A, did any subjects later satisfy criteria for group C (clinically significant PH with mean pulmonary artery pressure > 20 cmH2O and PVR ≥ 1.5 Wood unit) on RHC? Similarly, what percentage of subjects in group B later satisfied criteria for group C on repeat RHC indicated during routine clinical follow-up? Perhaps most importantly, among the 24 deaths in group A, were any deaths due to PH/heart failure? Any light that can be shed on the frequency of progression to clinically significant PH will help inform interval screening in patients with SCD initially deemed to be lower risk for PH. We advocate for longitudinal studies with repeat assessments of PH to better understand the overall risk of disease progression in our patients with sickle cell disease. Supplementary material is available at American Journal of Respiratory and Critical Care Medicine online. Please see the ICMJE disclosure forms, which have been provided as supplementary material.
Fields of Study & Subjects
Pulmonary Hypertension Research and Treatments
Hemoglobinopathies and Related Disorders
Congenital Heart Disease Studies
Publication details
- Journal / source
- American Journal of Respiratory and Critical Care Medicine
- Volume
- 212
- Issue
- 6
- Pages
- 1400–1400
- Publication date
- 20 March 2026
- Language
- EN